接受免疫检查点抑制剂患者的急性肾损伤:一项回顾性真实世界研究
该单中心回顾性队列纳入2011年12月至2020年8月接受免疫检查点抑制剂(ICPi)治疗的1037例癌症患者,189例(18.2%)发生急性肾损伤(AKI),其中37例(3.6%)为ICPi相关AKI。在治疗应答者中,非ICPi相关AKI与死亡风险升高相关(校正HR 2.03;95%CI 1.12-3.67),而ICPi相关AKI未与死亡风险升高相关(校正HR 0.60;95%CI 0.18-1.96)。ICPi相关AKI患者肾功能完全恢复比例低于非ICPi相关AKI患者(54% vs 79%,p=0.01)。
要点
- 1037例接受ICPi治疗患者中189例(18.2%)发生AKI,37例(3.6%)为ICPi相关AKI。
- 治疗应答者中非ICPi相关AKI与死亡风险升高相关(校正HR 2.03;95%CI 1.12-3.67)。
- ICPi相关AKI患者肾功能完全恢复比例低于非ICPi相关AKI(54% vs 79%,p=0.01)。
核心结论
- AKI在接受ICPi治疗的癌症患者中常见,ICPi相关AKI患者肾功能结局较其他原因AKI患者更差,但非ICPi相关AKI与更高的死亡风险相关,强调识别AKI不同亚表型的重要性。
研究设计与样本
- 单中心回顾性队列研究,纳入2011年12月至2020年8月接受ICPi治疗的患者,最终分析1037例,中位年龄63岁,60%为男性,22%存在既往慢性肾脏病。
主要发现
- 189例(18.2%)发生AKI,其中37例(3.6%)为ICPi相关AKI。
- 在进展期癌症患者中,AKI未与死亡率升高相关。
- 在治疗应答者中,非ICPi相关AKI与死亡风险升高相关(校正HR 2.03;95%CI 1.12-3.67),ICPi相关AKI未与死亡风险升高相关(校正HR 0.60;95%CI 0.18-1.96)。
- ICPi相关AKI患者较非ICPi相关AKI患者更可能具有更高的AKI分期,且更少实现肾功能完全恢复(54% vs 79%,p=0.01)。
关键数值与推荐
- AKI采用改善全球肾脏病预后组织(KDIGO)肌酐标准定义和分期。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors (ICPi) can cause immune-related adverse events (irAEs) including acute kidney injury (AKI). We investigated the incidence of ICPi-associated AKI (ICPi-AKI) and AKI from other causes (non-ICPi-AKI) in cancer patients treated with ICPi. METHODS: This was a single-centre retrospective cohort study of patients receiving ICPi therapy between December 2011 and August 2020. AKI was defined and staged by the Kidney Disease Improving Global Outcomes creatinine criteria. The primary outcome was the incidence of AKI and ICPi-AKI. RESULTS: A total of 1037 patients were included in the final analysis. The median age was 63 years, 60% were male, and 22% had pre-existing chronic kidney disease. Overall, 189 patients (18.2%) developed AKI of whom 37 patients (3.6%) had ICPi-AKI. In patients with progressive cancer, AKI was not associated with increased mortality. In treatment responders, non-ICPi-AKI was associated with an increased risk of mortality (adjusted hazard ratio [HR] 2.03; 95% confidence interval [CI] 1.12-3.67), whereas ICPi-AKI was not linked to an increased risk of death (adjusted HR 0.60; 95% CI 0.18-1.96). Patients with ICPi-AKI were more likely to have higher AKI stages and less likely to have complete kidney recovery compared with non-ICPi-AKI (54% versus 79%, p = 0.01). CONCLUSION: AKI was common in cancer patients treated with ICPi. Patients with ICPi-AKI had worse kidney outcomes compared to those with AKI from other causes. However, non-ICPi-AKI was associated with a higher risk of death. These findings emphasise the importance of identifying different sub-phenotypes of AKI.
引用
- Lumlertgul N, Vassallo P, Tydeman F, et al. Acute kidney injury in patients receiving immune checkpoint inhibitors: a retrospective real-world study. Eur J Cancer. 2023. PMID: 37499561. doi:10.1016/j.ejca.2023.112967
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。